Chronic graft versus host disease (cGVHD) is a life-threatening complication of allogeneic hematopoietic stem cell transplantation (HSCT). This study provides a systematic overview of evidence on the health-related quality of life (HRQoL) of patients with cGVHD. Systematic literature review was performed using PubMed. Literature search was limited to English-language articles published between 2007 and 2017. Included studies used the National Institutes of Health Consensus Criteria for diagnosing cGVHD and had a cohort size of at least 100 patients. Data from eligible studies were extracted describing the HRQoL instruments used, and reported HRQoL scores. Seventeen studies were included. Of the 8 HRQoL instruments used across these studies, the 36-item Short Form Health Survey (SF-36; n=14) and the Functional Assessment of Cancer Therapy - Bone Marrow Transplant (FACT-BMT; n=11) were applied most often. Only 1 study compared the HRQoL of HSCT recipients with and without cGVHD, in which cGVHD significantly impaired physical, psychological, social and spiritual HRQoL (p<0.05). cGVHD severity was found to significantly adversely affect patients’ HRQoL. Differences in HRQoL between moderate and severe cGVHD patients were greater than between mild and moderate cGVHD patients. Results indicate cGVHD mostly affects the physical domain of HRQoL. The impact of cGVHD on HRQoL varied by organ involvement; skin, gastrointestinal, lung and joint/fascia manifestations of cGVHD impaired patients’ HRQoL most significantly. Disease severity and organ involvement are both important predictors of HRQoL in cGVHD, and due to heterogeneity of organ involvement across patients, differences in magnitude of HRQoL impairment may be observed. New treatment options that improve the HRQoL in patients with cGVHD are needed. Further studies are also required to better understand the relationships between HRQoL, disease severity, and cGVHD symptoms (e.g. Lee Symptom Scale) between HSCT recipients with and without cGVHD.
Read full abstract